Newborn affected by maternal use of antidepressants
ICD-10 P04.15 is a billable code used to indicate a diagnosis of newborn affected by maternal use of antidepressants.
Newborns affected by maternal use of antidepressants may present with a range of symptoms due to in utero exposure to these medications. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), can cross the placenta and affect fetal development. Common manifestations in affected newborns include respiratory distress, feeding difficulties, irritability, and potential withdrawal symptoms. These infants may also exhibit signs of neonatal abstinence syndrome (NAS), which can complicate their clinical management. The timing of maternal medication use during pregnancy, dosage, and the specific type of antidepressant can influence the severity of symptoms. Clinicians must monitor these newborns closely for any complications and provide appropriate interventions, including supportive care and, if necessary, pharmacological treatment to manage withdrawal symptoms. Documentation should include maternal medication history, timing of exposure, and any observed symptoms in the newborn to ensure accurate coding and care planning.
Detailed records of maternal medication use, timing, and newborn symptoms.
Newborns presenting with irritability, feeding difficulties, or respiratory distress in the NICU.
Consideration of potential co-occurring conditions and the need for multidisciplinary care.
Comprehensive assessment of developmental milestones and ongoing monitoring of behavioral health.
Pediatric follow-up visits for newborns with a history of maternal antidepressant use.
Awareness of long-term developmental impacts and the need for early intervention services.
Used for newborns requiring assessment and management of symptoms related to maternal antidepressant use.
Complete documentation of maternal history and newborn assessment findings.
Neonatologists should ensure thorough evaluations to support coding.
Common symptoms include irritability, feeding difficulties, respiratory distress, and signs of withdrawal. Close monitoring is essential to manage these symptoms effectively.
